Effects of Dipyrone on Prostaglandin Production by Human Platelets and Cultured Bovine Aortic Endothelial Cells

Summary

Dipyrone and its metabolites 4-methylaminoantipyrine, 4-aminoantipyrine, 4-acetylaminoantipyrine and 4-formylaminoan- tipyrine inhibited the formation of thromboxane A₂ (TXA₂) during in vitro platelet aggregation induced by ADP, epinephrine, collagen, ionophore A23187 and arachidonic acid. Inhibition occurred after a short incubation (30–40 sec) and depended on the concentration of the drug or its metabolites and the aggregating agents. The minimal inhibitory concentration of dipyrone needed to completely block aggregation varied between individual donors, and related directly to the inherent capacity of their platelets to synthesize TXA₂.

Incubation of dipyrone with cultured bovine aortic endothelial cells resulted in a time and dose dependent inhibition of the release of prostacyclin (PGI₂) into the culture medium. However, inhibition was abolished when the drug was removed from the culture, or when the cells were stimulated to produce PGI₂ with either arachidonic acid or ionophore A23187.

These results indicate that dipyrone exerts its inhibitory effect on prostaglandins synthesis by platelets or endothelial cells through a competitive inhibition of the cyclooxygenase system.

Keywords

Dipyrone - Platelets - Endothelial cells - Thromboxane A₂ prostacyclin

• References

• 1 Joshua H, Rahamim S. Dipyrone as a potent in vitro and in vivo inhibitor of platelet aggregation. Harefuah 1978; 95: 253-255
• 2 Weinberger I, Joshua H, Friedmann J, Rahamim S, Agmon J. Inhibition of ADP-induced platelet aggregation by dipyrone in patients with acute myocardial infarction. Thromb Haemostas 1979; 42: 752-756
• 3 Fuster V, Chesebro JH. Antithrombotic therapy: role of platelet inhibitor drugs. II. Pharmacologic effects of platelet inhibitor drugs. Mayo Clin Proc 1981; 56: 185-195
• 4 Ali M, McDonald JWD. Effects of sulfinpyrazone on platelet prostaglandin synthesis and platelet release of serotonin. J Lab Clin Med 1977; 80: 868-875
• 5 Gospodarowicz D, Moran J, Braun D, Birdwell C. Clonal growth of bovine vascular endothelial cells: Fibroblast growth factor as a survival agent. Proc Natl Acad Sci USA 1976; 73: 4120-4124
• 6 Gospodarowicz D, Bialecki H, Greenburg G. Purification of fibroblast growth factor activity from bovine brain. J Biol Chem 1978; 253: 3736-3743
• 7 Eldor A, Falcone DJ, Hajjar DP, Minick CR, Weksler BB. Recovery of prostacyclin production by de-endothelialized rabbit aorta: Critical role of neointimal smooth muscle cells. J Clin Invest 1981; 67: 735-741
• 8 Levin RI, Jaffe EA, Weksler BB, Tack-Goldman T. Nitroglycerin stimulates synthesis of prostacyclin by cultured human endothelial cells. J Clin Invest 1981; 67: 762-769
• 9 Bauminger S, Zor U, Lindner HR. Radioimmunological assay of prostaglandin synthetase activity. Prostaglandins 1973; 4: 313-324
• 10 Koh H, Inone A, Mashimo N, Numano F, Maezawa H. A radioimmunoassay of thromboxane B₂ with thromboxane B₂ ¹²⁵I tyramide and its application to the study on thromboxane B₂ formation during platelet aggregation. Thromb Res 1980; 17: 403-413
• 11 Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthetase by aspirin. Proc Natl Acad Sri USA 1975; 72: 3073-3076
• 12 Weksler BB, Marcus AJ, Jaffe EA. Synthesis of prostaglandin I₂ (prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acad Sri USA 1977; 74: 3922-3926
• 13 Fuster V, Chesebro JH. Antithrombotic therapy: Role of platelet inhibitor drugs. III. Management of arterial thromboembolic and atherosclerotic disease. Mayo Clin Proc 1981; 56: 264-273
• 14 Burch JW, Baenziger NL, Stanford N, Majerus PW. Sensitivity of fatty arid cyclooxygenase from human aorta to acetylation by aspirin. Proc Natl Acad Sri USA 1978; 75: 5181-5184
• 15 Gordon JL, Pearson JD. Effects of sulphinpyrazone and aspirin on prostaglandin (prostacyclin) synthesis by endothelial cells. Br J Pharmacol 1978; 64: 481-483
• 16 Steele P, Rainwater J. Favorable effect of sulfinpyrazone on thromboembolism in patients with rheumatic heart disease. Circulation 1980; 62: 462-465
• 17 Steele P, Rainwater J, Vogel R, Genton E. Platelet suppressant therapy in patients with coronary artery disease. JAMA 1978; 240: 228-231
• 18 The Anturan Reinfarction Trial Research Group. Sulphinpyrazone in the prevention of cardiac death after myocardial infarction. The Anturan reinfarction trial. N Engl J Med 1978; 298: 289-295
• 19 Steele P, Carroll J, Overfield D, Genton E. Effect of sulfinpyrazone on platelet survival time in patients with transient cerebral ischemic attacks. Stroke 1977; 8: 396-398
• 20 Steele P, Ellis J, Genton E. Effects of platelet suppressant anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. Am J Med 1978; 64: 441-445
• 21 Kaegi A, Pineo GF, Shimizu A, Trivedi H, Hirsh J, Gent M. Arteriovenous-shunt thrombosis. Prevention by sulphinpyrazone. N Engl J Med 1974; 290: 304-306
• 22 Levy M. Epidemiology evaluation of rare side-effects of mild analgesics. Br J Oin Pharmacol 1980; 10: 3985-3995